Show simple item record

Authordc.contributor.authorSharma, S. 
Authordc.contributor.authorBabiker, A.G. 
Authordc.contributor.authorEmery, S. 
Authordc.contributor.authorGordin, F.M. 
Authordc.contributor.authorLundgren, J.D. 
Authordc.contributor.authorNeaton, J.N. 
Authordc.contributor.authorBakowska, E. 
Authordc.contributor.authorSchechter, M. 
Authordc.contributor.authorWiselka, M.J. 
Authordc.contributor.authorWolff Reyes, Marcelo 
Admission datedc.date.accessioned2015-08-21T18:17:16Z
Available datedc.date.available2015-08-21T18:17:16Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationHIV Medicine (2015), 16 (Suppl. 1), 30–36en_US
Identifierdc.identifier.otherDOI: 10.1111/hiv.12231
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/133007
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractObjectives The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV-positive individuals with CD4 cell counts above 500 cells/μL. We describe the demographics, HIV-specific characteristics and medical history of this cohort. Methods Data collected at baseline include demographics, HIV-specific laboratory values, prior medical diagnoses and concomitant medications. Baseline characteristics were compared by geographical region, gender and age. Results START enrolled 4685 HIV-positive participants from 215 sites in 35 countries. The median age is 36 years [interquartile range (IQR) 29–44 years], 27% are female, and 45% self-identify as white, 30% as black, 14% as Latino/Hispanic, 8% as Asian and 3% as other. The route of HIV acquisition is reported as men who have sex with men in 55% of participants, heterosexual sex in 38%, injecting drug use in 1% and other/unknown in 5%. Median time since HIV diagnosis is 1.0 year (IQR 0.4–3.0 years) and the median CD4 cell count and HIV RNA values at study entry are 651 cells/μL (IQR 584–765 cells/μL) and 12 754 HIV RNA copies/mL (IQR 3014–43 607 copies/mL), respectively. Conclusions START has enrolled a diverse group of ART-naïve individuals with high CD4 cell counts who are comparable to the HIV-positive population from the regions in which they were enrolled. The information collected with this robust study design will provide a database with which to evaluate the risks and benefits of early ART use for many important outcomes.en_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherBritish HIV Associationen_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectClinical trialen_US
Keywordsdc.subjectHIVen_US
Keywordsdc.subjectSTART trialen_US
Keywordsdc.subjectWhen to start antiretroviral therapyen_US
Títulodc.titleDemographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialen_US
Document typedc.typeArtículo de revistaen_US


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile